The learning objectives as below: 

  1. Describe the mechanisms and structural components of the modern ADCs in breast cancer 
  2. Summarize the key phase III clinical trials that led to the approval of the 4 ADCs 
  3. Learn about the current data on clinical response or resistance through available biomarkers 
  4. Discuss about sequencing of ADCs 
  5. Other ADCs under development
Session date: 
11/13/2025 - 8:00am to 9:00am CST
Add to calendar: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
Please login or create an account to proceed.
Speaker Name: 
Maria Moscvin, MD